Last reviewed · How we verify
BPX-04 1% minocycline topical gel
BPX-04 1% minocycline topical gel is a Small molecule drug developed by BioPharmX, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | BPX-04 1% minocycline topical gel |
|---|---|
| Sponsor | BioPharmX, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PHASE2)
- Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPX-04 1% minocycline topical gel CI brief — competitive landscape report
- BPX-04 1% minocycline topical gel updates RSS · CI watch RSS
- BioPharmX, Inc. portfolio CI
Frequently asked questions about BPX-04 1% minocycline topical gel
What is BPX-04 1% minocycline topical gel?
BPX-04 1% minocycline topical gel is a Small molecule drug developed by BioPharmX, Inc..
Who makes BPX-04 1% minocycline topical gel?
BPX-04 1% minocycline topical gel is developed by BioPharmX, Inc. (see full BioPharmX, Inc. pipeline at /company/biopharmx-inc).
What development phase is BPX-04 1% minocycline topical gel in?
BPX-04 1% minocycline topical gel is in Phase 1.